Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Inno Biologics
Nilai (Putra Nilai), Negeri Sembilan, Malaysia
- Ownership
- Private
- Development stage
- Other
01
Overview
Inno Biologics has successfully completed production and delivery of biosimilar erythropoietin for Phase 1 trials in India, novel monoclonal antibodies for Phase 1 trials in Korea, and is supporting Phase 2 trials for brain tumor therapies in Korea. Its platform manufacturing shows higher product yields and comparable quality to reference products
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- Monoclonal antibodyRecombinant proteinPeptidesPolyclonal antibody
- Industry
- Biotech
02
Partnerships
CEVEC Pharmaceuticals (licensed CAP™ expression system technology)Boehringer Ingelheim (Production Alliance Network Biologics)MIT Centre for Biomedical Innovation (CBI)
Beyond the preview
Go deeper on Inno Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inno Biologics.